Adult

Dalbavancin

General Information

Glycopeptide

Restricted formulary antimicrobial: For details see OUH netFormulary

AWaRe antibiotic classification: 'Reserve'. All indications to be discussed with Micro/ID

For all information regarding interactions, contraception, pregnancy and breastfeeding and additional information, see BNF and Summary of Product Characteristics (SPC).

Standard Dose

  Intravenous dose
Standard dose

1500 mg for 1 dose

OR

1000mg (day 1) followed by 500 mg one week later (day 8)

Obesity

No dose adjustment required

Renal and hepatic impairment

Renal impairment (Note: dose ranges use creatinine clearance, rather than eGFR)

Creatinine Clearance 30ml/min and over: Dose as in normal renal function

Creatinine Clearance less than 30ml/min: See table below:

  Intravenous dose

Where creatinine clearance less than 30ml/min

(Repeat U&Es on day 8)

1g single dose

OR

750mg (day 1) followed by 375mg one week later (day 8)

OR

750mg (day 1) followed by 500mg one week later (day 8) if creatinine clearance improves to 30ml/min or over by day 8

HD/HDF/High flux

Not dialysed. Dose as in normal renal function.

Can be administered without regard to the timing of haemodialysis.

 

Hepatic impairment

Mild hepatic impairment (Child-Pugh Class A): No dose adjustment 

Moderate or Severe hepatic impairment (Child-Pugh Class B or Class C): Use with caution as no data are available to determine appropriate dosing.

References

  1. ADVANZ Pharma. Xydalba 500 mg powder for concentrate for solution for infusion summary of product characteristics. Electronic medicines compendium. Last revision of the text 17/7/25. Accessed via www.medicines.org.uk Accessed 21/4/26.
  2. British National Formulary. Dalbavancin. BNF online accessed via www.medicinescomplete.com  Accessed 21/4/26.
  3. The Renal Drug database. Dalbavancin. Last updated 31/10/23. Accessed via https://renaldrugdatabase.com Accessed 21/4/26.
  4. Sanford Guide [online]. Dalbavancin. Last updated 31/3/26. Accessed via https://webedition.sanfordguide.com Accessed 21/4/26.

Editorial Information

Last reviewed: 21 Apr 2026

Next review date: 20 Apr 2029

Author(s): AMST.